Company intelligence / Profile preview
Kallyope
- Ownership
- Private
- Employees
- ~91
- Development stage
- Other
Overview
Kallyope has advanced multiple programs targeting the gut-brain axis into clinical development. As of recent updates, two novel compounds are in clinical trials addressing major metabolic and neurological indications. The company leverages its proprietary Klarity™ platform to identify new therapeutic opportunities by decoding gut-brain signaling. It has published significant findings and holds numerous patents related to its discoveries.
- Therapeutic areas
- ImmunologyNeurologyMetabolic Disorders
- Modalities
- Small molecules (gut-restricted agents)Plant-based bioactives (via collaboration)Nutritional products (potentially)
- Industry
- Biotech
Drug pipeline
10 assets9 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Kallyope.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kallyope.